The Next Leap

Thierry Heles

A researcher makes a promising discovery in a lab – a drug like warfarin, the covid vaccine, or a way to build quantum computers. What happens next decides whether the idea ever reaches a patient, a factory or a customer. The Next Leap is about that stretch of work: the part between a promising result and a company. Thierry Heles talks with the people who make those calls: tech transfer officers who decide which inventions get a full patent filing and which are dropped, venture capital investors who explain why a brilliant researcher still gets turned down for funding, founders who describe the licensing clause that nearly killed their deal, and lawyers who sort out who owns an idea. Each conversation focuses on the decisions themselves: what evidence convinced someone to invest, what mistake cost a team a year, and what the people who got it right did differently. You won't get a lecture on theory. You'll hear practitioners explain their reasoning in the situations they actually faced. If you're a researcher wondering what happens after you publish, a founder negotiating your first licence, or simply curious how the products around you got made, this is for you.

  1. Mar 3

    Brechtje Vreenegoor, Sebastiaan Berendse: In agriculture, spinouts need to reform the whole system

    Wageningen University & Research is a truly unique organisation combining a higher education institution with an applied research institute. This dual nature makes commercialising research an interesting challenge, particularly with Wageningen's focus on agtech and food tech, where, for decades, each component in the supply chain has been optimised for cost. So, how do you give spinouts a fighting chance? We also look at the Netherlands' recent update to its national deal term principles, which Brechtje Vreenegoor was involved in creating, and we analyse how these principles strike a balance between the university’s interests and those of founders and investors. Then, we consider how Wageningen University & Research operates a unique pre-incubation programme designed to support researchers and students developing agricultural and food technology startups. This model focuses on validating ideas through a multi-stage process, including feasibility studies and proof-of-concept funding, rather than immediately seeking venture capital. And finally, Sebastiaan Berendse looks at Wageningen's approach to venture capital funds, why its LP commitments are not just about capital but also drawing investors to campus, and why Graduate Ventures – which currently covers Delft and Rotterdam – is an enticing proposition for Wageningen's ecosystem, which desperately needs more pre-seed cash.

About

A researcher makes a promising discovery in a lab – a drug like warfarin, the covid vaccine, or a way to build quantum computers. What happens next decides whether the idea ever reaches a patient, a factory or a customer. The Next Leap is about that stretch of work: the part between a promising result and a company. Thierry Heles talks with the people who make those calls: tech transfer officers who decide which inventions get a full patent filing and which are dropped, venture capital investors who explain why a brilliant researcher still gets turned down for funding, founders who describe the licensing clause that nearly killed their deal, and lawyers who sort out who owns an idea. Each conversation focuses on the decisions themselves: what evidence convinced someone to invest, what mistake cost a team a year, and what the people who got it right did differently. You won't get a lecture on theory. You'll hear practitioners explain their reasoning in the situations they actually faced. If you're a researcher wondering what happens after you publish, a founder negotiating your first licence, or simply curious how the products around you got made, this is for you.